ArticleJournal of translational medicine2016
Hericium erinaceus mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade.
Article in Journal of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 71 citations in OpenAlex.
- The Cerebral Protective Effect of Novel Erinacines fromAntioxidants (Basel, Switzerland) · 2024Article
- Antioxidative Activities of Micronized Solid-State CultivatedMolecules (Basel, Switzerland) · 2023Article
- Article
- Neuroprotective Effects of Erinacine A on an Experimental Model of Traumatic Optic Neuropathy.International journal of molecular sciences · 2023Article
- Leaky Gut and the Ingredients That Help Treat It: A Review.Molecules (Basel, Switzerland) · 2023Review
- Neurogenesis-dependent antidepressant-like activity of Hericium erinaceus in an animal model of depression.Chinese medicine · 2021Article
- Erinacine A-EnrichedNutrients · 2021Article
- Preclinical Bioavailability, Tissue Distribution, and Protein Binding Studies of Erinacine A, a Bioactive Compound fromMolecules (Basel, Switzerland) · 2021Article
- Hericium erinaceus mycelium and its small bioactive compounds promote oligodendrocyte maturation with an increase in myelin basic protein.Scientific reports · 2021Article
- The effect of Hericium erinaceum on the prevention of chemically induced experimental colitis in rats.The Korean journal of internal medicine · 2021Article
- Retraction Note to: Hericium erinaceus mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade.Journal of translational medicine · 2021Article
- Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials.International journal of molecular sciences · 2021Review
- Optimization of Ultrasonic Extraction to Obtain Erinacine A and Polyphenols with Antioxidant Activity from the Fungal Biomass ofFoods (Basel, Switzerland) · 2020Article
- Potential Antidepressant Effects of Scutellaria baicalensis, Hericium erinaceus and Rhodiola rosea.Antioxidants (Basel, Switzerland) · 2020Review
- Post-Treatment with Erinacine A, a Derived Diterpenoid ofAntioxidants (Basel, Switzerland) · 2020Article
- Prevention of Early Alzheimer's Disease by Erinacine A-EnrichedFrontiers in aging neuroscience · 2020Article
- Therapeutic Potential ofInternational journal of molecular sciences · 2019Review
- Lion's Mane Mushroom,Antioxidants (Basel, Switzerland) · 2019Article
- Absolute Bioavailability, Tissue Distribution, and Excretion of Erinacine S inMolecules (Basel, Switzerland) · 2019Article
- The Neuroprotective Effect ofInternational journal of molecular sciences · 2019Article
Corrections and comments
- Retraction · 2021-02-15Conflict of Interest · Duplication of/in Image ·
- Retracted
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHericium erinaceus is an edible mushroom; its various pharmacological effects which have been investigated. This study aimed to demonstrate whether efficacy of oral administration of H. erinaceus mycelium (HEM) and its isolated diterpenoid derivative, erinacine A, can act as an anti-neuroinflammatory agent to bring about neuroprotection using an MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease, which results in motor disturbances, in addition to elucidating the mechanisms involved.
methodsMice were treated with and without HEM or erinacine A, after MPTP injection for brain injuries by the degeneration of dopaminergic nigrostriatal neurons. The efficacy of oral administration of HEM improved MPTP-induced loss of tyrosine hydroxylase positive neurons and brain impairment in the substantia nigra pars compacta as measured by brain histological examination.
resultsTreatment with HEM reduced MPTP-induced dopaminergic cell loss, apoptotic cell death induced by oxidative stress, as well as the level of glutathione, nitrotyrosine and 4-hydroxy-2-nonenal (4-HNE). Furthermore, HEM reversed MPTP-associated motor deficits, as revealed by the analysis of rotarod assessment. Our results demonstrated that erinacine A decreases the impairment of MPP-induced neuronal cell cytotoxicity and apoptosis, which were accompanied by ER stress-sustained activation of the IRE1α/TRAF2, JNK1/2 and p38 MAPK pathways, the expression of C/EBP homologous protein (CHOP), IKB-β and NF-κB, as well as Fas and Bax.
conclusionThese physiological and brain histological changes provide HEM neuron-protective insights into the progression of Parkinson's disease, and this protective effect seems to exist both in vivo and in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.